Advances in pneumococcal vaccines: What are the advantages for the elderly?

Drugs and Aging

Volumn 24, Issue 10, 2007, Pages

  Vila Córcoles, Angel ^a  

^a INSTITUT CATALÀ DE LA SALUT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATE PNEUMOCOCCAL VACCINE; INFLUENZA VACCINE; PNEUMOCOCCAL HISTIDINE TRIAD PROTEIN B; PNEUMOCOCCAL SURFACE ADHESIN A; PNEUMOCOCCAL SURFACE PROTEIN C; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; POLYSACCHARIDE PNEUMOCOCCAL VACCINE; PROTEIN; PROTEIN BASED PNEUMOCOCCAL VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DESIGN; DRUG FORMULATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEROTYPE; VACCINATION; VIRULENCE;

EID: 35048837570     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200724100-00001     Document Type: Review

References (65)

1. Butler JC, Schuchat A. Epidemiology of pneumococcal infections in the elderly. Drugs Aging 1999; 15 Suppl. 1: 11-9
2. Ortqvist A, Hedlund J, Kalin M. Streptococcus pneumoniae: epidemiology, risk factors, and clinical features. Semin Respir Crit Care Med 2005; 26 (6): 563-74
3. Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999; 15 Suppl. 1: 21-30
4. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis 2005; 5 (2): 83-93
5. Rubins JB, Janoff EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging 2001; 18 (5): 305-11
6. Ortqvist A. Pneumococcal vaccination: current and future issues. Eur Respir J 2001; 18 (1): 184-95
7. Bogaert D, Hermans PW, Adrian PV, et al. Pneumococcal vaccines: an update on current strategies. Vaccine 2004; 22 (17-18): 2209-20
8. Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia (PA): Saunders, 2003: 529-88
9. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR Morb Mortal Wkly Rep 1997; 46 (RR-8): 1-24
10. Sankilampi U, Honkanen PO, Bloigu A, et al. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996; 173: 387-93
11. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16 (2): 308-18
12. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994; 154: 2666-77
13. Hutchison BG, Oxman AD, Shannon HS, et al. Clinical effectiveness of pneumococcal vaccine: meta-analysis. Can Fam Physician 1999; 45: 2381-93
14. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000; 1: 1
15. Cornu C, Yzebe D, Leophonte P, et al. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001; 19: 4780-90
16. Puig-Barbera J, Belenguer Varea A, Goterris-Pinto M, et al. Pneumococcal vaccine effectiveness in the elderly: systematic review and meta-analysis [in Spanish]. Aten Primaria 2002; 30 (5) 269-81.
17. Mantagni P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003; 3: 71-8
18. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20: 2166-73
19. Dear K, Holden J, Andrews R, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2003; (4): CD000422
20. Fedson DS, Lise C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22: 927-46
21. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine: part I. Efficacy of PPV in the elderly: comparison of meta-analyses. Eur J Epidemiol 2004; 19: 353-63
22. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumcoccal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-55
23. Andrews R, Counahan M, Hogg G, et al. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Vaccine 2004; 23: 132-8
24. Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363-8
25. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43 (7): 860-8
26. Honkanen PO, Keistinen T, Miettinen L, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17 (20-21): 2493-500
27. Mykietiuk A, Carratala J, Dominguez A, et al. Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. Eur J Clin Microbiol Infect Dis 2006; 25 (7): 457-62
28. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278 (16): 1333-9
29. Ament A, Baltussen R, Duru G, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000; 31: 444-50
30. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine: part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004; 19: 365-75
31. Obaro SK. The new pneumococcal vaccine. Clin Microbiol Infect 2002; 8 (10): 623-33
32. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-46
33. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal disease: United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005; 54 (36): 893-7
34. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005; 294 (16): 2043-51
35. Moore MR, Pilishvili T, Bennett NM, et al. Age-specific trends in invasive pneumococcal disease among adults: evidence for indirect effects of conjugate use among children: selected US sites, 1998-2004 [abstract no. PO418]. Fifth International Symposium on Pneumococci and Pneumococcal Diseases; 2006 Apr 2-6; Alice Springs (NT)
36. Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Rev Vaccines 2006; 5 (4): 553-64
37. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354: 1455-63
38. Fry AM, Zell ER, Schuchat A, et al. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002; 21: 303-11
39. Abraham-Van Parijs B. Review of pneumococcal conjugate vaccine in adults: implications on clinical development. Vaccine 2004; 22 (11-12): 1362-71
40. Lucero MG, Dulalia VE, Parreno RN, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev 2004; (4): CD004977
41. Powers DC, Anderson EL, Lottenbach K, et al. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173: 1014-8
42. Wuorimaa T, Kayhty H, Leroy O, et al. Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults. Vaccine 2001; 19 (15-16): 1863-9
43. Jackson LA, Neuzil KM, Whitney CG, et al. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005; 23 (28): 3697-703
44. De Roux A, Kuhnke A, Schmole-Thoma B, et al. Immunogenecity, safety and tolerability of a seven valent pneumococcal conjugate (7vPnC) and pneumococcal polysaccharide (23vPnS) vaccine booster dose 12 months after first injection in elderly individuals [abstract no. 980]. Annual Meeting of Infectious Disease Society of America; 2005 Oct 5-9; San Francisco (CA)
45. Shelly MA, Jacoby H, Riley GJ, et al. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65: 242-7
46. Feikin DR, Klugman KP, Facklam RR, et al. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis 2005; 41: 481-7
47. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-8
48. Clinical trial: assess the immunogenicity of GSK biologicals' 10-valent pneumococcal conjugate vaccine [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00307541 [Accessed 2007 Jan 10]
49. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367 (9512): 740-8
50. Wuorimaa TK, Dagan R, Bailleux F, et al. Functional activity of antibodies after immunization of Finnish and Israeli infants with an 11-valent pneumococcal conjugate vaccine. Vaccine 2005; 23 (46-47): 5328-32
51. Clinical trial: study evaluating pneumococcal vaccine in healthy infants [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00205803 [Accessed 2007 Jan 10]
52. Briles DE. Protection of the elderly from pneumococcal pneumonia with a protein-based vaccine? Mech Ageing Dev 2004; 25 (2): 129-31
53. Tai SS. Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies. Crit Rev Microbiol 2006; 32 (3): 139-53
54. Garcia-Suarez MM, Vazquez F, Mendez FJ. Streptococcus pneumoniae virulence factors and their clinical impact: an update. Enferm Infecc Microbiol Clin 2006; 24 (8): 512-7
55. Wu HY, Nahm MH, Guo Y, et al. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997; 175 (4): 839-46
56. Arulanandam BP, Lynch JM, Briles DE, et al. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001; 69 (11): 6718-24
57. Seo JY, Seong SY, Ahn BY, et al. Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun 2002; 70 (3): 1143-9
58. Nabors GS, Braun PA, Herrmann DJ, et al. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 2000; 18 (17): 1743-54
59. Moore QC, Bosarge JR, Quin LR, et al. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine 2006; 24 (29-30): 5755-61
60. Ogunniyi AD, Grabowicz M, Briles DE, et al. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007; 75 (1): 350-7
61. Baril L, Briles DE, Crozier P, et al. Characterization of antibodies to PspA and PsaA in adults over 50 years of age with invasive pneumococcal disease. Vaccine 2004; 23 (6): 789-93
62. Baril L, Dietemann J, Essevaz-Roulet M, et al. Pneumococcal surface protein A (PspA) is effective at eliciting T cell-mediated responses during invasive pneumococcal disease in adults. Clin Exp Immunol 2006; 145 (2): 277-86
63. Linder A, Hollingshead S, Janulczyk R, et al. Human antibody response towards the pneumococcal surface proteins PspA and PspC during invasive pneumococcal infection. Vaccine 2007; 25 (2): 341-5
64. Kirkham LA, Kerr AR, Douce GR, et al. Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 2006; 74 (1): 586-93
65. Audouy SA, van Roosmalen ML, Neef J, et al. Lactococcus actis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 2006; 24 (26): 5434-41